24-methyl-5β-cholanetriol-(3α.7α.12α) | 98424-28-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 24-methyl-5β-cholanetriol-(3α.7α.12α)
• 英文别名: 3α.7α.12α-Trihydroxy-10.13-dimethyl-17β-((R)-1-methyl-pentyl)-5β-gonan；24-Methyl-5β-cholantriol-(3α.7α.12α)；(10S)-3t.7t.12t-Trihydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-pentyl)-(5cH.8cH.9tH.14tH)-hexadecahydro-1H-cyclopenta[a]phenanthren；(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-17-[(2R)-hexan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
• CAS: 98424-28-3；103188-82-5
• 化学式: C₂₅H₄₄O₃
• 分子量: 392.623
• InChiKey: KXKPFWURUKNKBM-WKJAYYNJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  24-methyl-5β-cholanetriol-(3α.7α.12α) 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 24-methyl-5β-cholane-3,7,12-trione
  参考文献：
  名称：

  Masui; Kazuno, Journal of Biochemistry, 1962, vol. 51, p. 119,122

  摘要：

  DOI：
• 作为产物：
  描述：

  24-methylene-5β-cholanetriol-(3α,7α,12α) 在 溶剂黄146 、 铂 作用下， 生成 24-methyl-5β-cholanetriol-(3α.7α.12α)
  参考文献：
  名称：

  Masui; Kazuno, Journal of Biochemistry, 1962, vol. 51, p. 119,122

  摘要：

  DOI：

文献信息

• CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：SAVAGE PAUL B.

  公开号：US20100330086A1

  公开（公告）日：2010-12-30

  The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

  该发明提供了用于在体外、体外或体内减少或抑制细胞感染或发病的疱疹病毒科（HV）的方法，症状或病理与体外、体外或体内疱疹病毒科（HV）感染或发病相关，或在体外、体外或体内疱疹病毒科（HV）感染或发病的不良副作用。在一种实施方式中，该发明的方法包括使用一种发明化合物（例如，阳离子类固醇抗菌药物或CSA）治疗受试者。
• APJ Receptor Compounds
  申请人：ANCHOR THERAPEUTICS, INC.

  公开号：US20160159861A1

  公开（公告）日：2016-06-09

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

  本发明涉及一般意义上的化合物，它们是G蛋白偶联受体apelin的变构调节剂（例如，负和正的变构调节剂，变构激动剂和激动-变构调节剂）。APJ受体化合物源自APJ受体的细胞内环和结构域。本发明还涉及使用这些APJ受体化合物和包含APJ受体化合物的药物组成物治疗与APJ受体调节相关的疾病和病况，例如心血管疾病（例如高血压和心力衰竭，如充血性心力衰竭）、癌症、糖尿病、干细胞移植、液体稳态、细胞增殖、免疫功能、肥胖症、转移性疾病和HIV感染。
• CATIONIC STEROIDAL ANTIMICROBIAL COMPOUNDS
  申请人：Savage Paul B.

  公开号：US20150239928A1

  公开（公告）日：2015-08-27

  Disclosed herein are cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSAs. CSAs may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSAs.

  本文揭示了阳离子类固醇抗微生物剂（“CSAs”或“ceragenins”）及其制备方法。特别有利的方法被确定用于合成CSAs。CSAs可以制成用于治疗对CSAs有响应的疾病的受试者，包括但不限于治疗细菌感染。因此，一些实施例包括CSAs的配方和给药方法。
• Kurauti; Kazuno, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1939, vol. 262, p. 53,56
  作者：Kurauti、Kazuno

  DOI：——

  日期：——
• Kuroda, Journal of Biochemistry, 1953, vol. 40, p. 169,171
  作者：Kuroda

  DOI：——

  日期：——